Firm that called EXACT PEAK of the Dot Com boom...just issued another major prediction.
If you’ve got money invested in the market – and especially in these 5 popular tech stocks – this is critical information for the days ahead…

NASDAQ:ABMD - Abiomed Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $351.25
  • Forecasted Upside: 9.19 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$321.70
▼ -5.49 (-1.68%)

This chart shows the closing price for ABMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abiomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABMD

Analyst Price Target is $351.25
▲ +9.19% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Abiomed in the last 3 months. The average price target is $351.25, with a high forecast of $425.00 and a low forecast of $245.00. The average price target represents a 9.19% upside from the last price of $321.70.

This chart shows the closing price for ABMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
Legend Who Bought Amazon In 1998 Says: Now Is The Time
Wall street legend Chris Rowe says there’s a huge stock market event looming - and he’s revealing his #1 pick for free.
pixel

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Abiomed. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$360.00High
6/6/2021SVB LeerinkReiterated RatingHoldLow
1/29/2021SVB LeerinkBoost Price TargetMarket Perform$320.00 ➝ $375.00Medium
1/29/2021Morgan StanleyBoost Price TargetUnderweight$238.00 ➝ $245.00Medium
1/28/2021Piper SandlerBoost Price TargetOverweight$350.00 ➝ $425.00High
12/21/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$280.00 ➝ $320.00High
12/15/2020Morgan StanleyBoost Price TargetUnderweight$217.00 ➝ $238.00Medium
10/12/2020SVB LeerinkLower Price TargetMarket Perform$335.00 ➝ $280.00Medium
8/7/2020Morgan StanleyBoost Price TargetUnderweight$152.00 ➝ $217.00Medium
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$280.00 ➝ $335.00Low
7/13/2020OTR GlobalUpgradePositiveHigh
5/28/2020SVB LeerinkBoost Price TargetMarket Perform$195.00 ➝ $225.00Low
5/27/2020BTIG ResearchDowngradeHoldHigh
5/1/2020Morgan StanleyBoost Price TargetUnderweight$149.00 ➝ $152.00Medium
4/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$220.00 ➝ $175.00High
3/27/2020Morgan StanleyLower Price TargetUnderweight$165.00 ➝ $149.00Low
3/23/2020Piper SandlerReiterated RatingBuy$240.00High
3/23/2020StephensLower Price TargetOverweight$240.00 ➝ $155.00High
2/11/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$198.00 ➝ $165.00High
2/6/2020BTIG ResearchInitiated CoverageHoldHigh
12/17/2019Morgan StanleyLower Price TargetEqual Weight$215.00 ➝ $198.00Low
11/1/2019SVB LeerinkBoost Price TargetOutperform$195.00 ➝ $240.00High
10/29/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/30/2019William BlairReiterated RatingBuyLow
8/2/2019William BlairReiterated RatingBuyLow
8/2/2019GuggenheimDowngradeBuy ➝ NeutralMedium
8/1/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$325.00 ➝ $215.00Medium
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
5/7/2019BTIG ResearchReiterated RatingBuyLow
5/3/2019SunTrust BanksReiterated RatingBuy$340.00Low
1/22/2019BTIG ResearchReiterated RatingBuy$400.00Low
1/2/2019Morgan StanleyLower Price TargetOverweight ➝ Overweight$496.00 ➝ $461.00High
11/7/2018Morgan StanleyUpgradeEqual ➝ Equal Weight$396.00 ➝ $496.00Medium
11/2/2018BTIG ResearchUpgradeNeutral ➝ Buy$450.00Low
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$370.00 ➝ $396.00High
6/22/2018Piper Jaffray CompaniesBoost Price TargetOverweight$360.00 ➝ $480.00High
5/29/2018Jefferies Financial GroupBoost Price TargetBuy$460.00Medium
5/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$360.00High
5/1/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$259.00 ➝ $320.00Medium
4/4/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$332.00Medium
2/16/2018SunTrust BanksReiterated RatingBuy$370.00N/A
2/4/2018BTIG ResearchReiterated RatingHoldHigh
2/2/2018SVB LeerinkBoost Price TargetOutperform$300.00Low
2/2/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$204.00 ➝ $259.00Low
2/2/2018GuggenheimReiterated RatingBuy$280.00Medium
2/1/2018Jefferies Financial GroupReiterated RatingBuy$300.00Medium
2/1/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$220.00 ➝ $300.00Medium
1/19/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $265.00Low
1/12/2018Jefferies Financial GroupBoost Price TargetBuy$250.00Medium
1/4/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
12/21/2017Jefferies Financial GroupBoost Price TargetBuy$208.00 ➝ $220.00Medium
11/1/2017SunTrust BanksReiterated RatingBuy$195.00N/A
10/29/2017BTIG ResearchReiterated RatingHoldN/A
10/26/2017Piper Jaffray CompaniesBoost Price TargetOverweight$200.00N/A
10/16/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/12/2017SVB LeerinkReiterated RatingOutperform$180.00 ➝ $200.00N/A
9/29/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$195.00High
9/29/2017Jefferies Financial GroupBoost Price TargetBuy$175.00 ➝ $208.00High
8/29/2017Piper Jaffray CompaniesReiterated RatingBuy$160.00Low
8/29/2017Jefferies Financial GroupReiterated RatingBuy$175.00Low
8/4/2017Jefferies Financial GroupBoost Price TargetBuy$165.00 ➝ $175.00Low
7/27/2017Piper Jaffray CompaniesReiterated RatingOverweight$145.00 ➝ $160.00Medium
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 ➝ $140.00Low
7/4/2017Piper Jaffray CompaniesSet Price Target$145.00Low
6/8/2017William BlairReiterated RatingOutperform ➝ OutperformLow
4/6/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$145.00Medium
3/30/2017SVB LeerinkBoost Price TargetOutperform$140.00 ➝ $150.00Low
1/8/2017BTIG ResearchReiterated RatingBuy$170.00N/A
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/A
9/28/2016SVB LeerinkReiterated RatingOutperform$125.00N/A
8/9/2016Jefferies Financial GroupBoost Price TargetBuy$130.00 ➝ $145.00N/A
7/29/2016Jefferies Financial GroupBoost Price TargetBuy$125.00 ➝ $130.00N/A
(Data available from 6/23/2016 forward)
Abiomed logo
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More

Today's Range

Now: $321.70
Low: $319.32
High: $328.00

50 Day Range

MA: $302.51
Low: $262.71
High: $351.17

52 Week Range

Now: $321.70
Low: $234.39
High: $387.40

Volume

265,975 shs

Average Volume

305,684 shs

Market Capitalization

$14.57 billion

P/E Ratio

65.25

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Abiomed?

The following Wall Street sell-side analysts have issued research reports on Abiomed in the last twelve months: Deutsche Bank Aktiengesellschaft, Morgan Stanley, OTR Global, Piper Sandler, SVB Leerink LLC, and TheStreet.
View the latest analyst ratings for ABMD.

What is the current price target for Abiomed?

4 Wall Street analysts have set twelve-month price targets for Abiomed in the last year. Their average twelve-month price target is $351.25, suggesting a possible upside of 7.4%. Piper Sandler has the highest price target set, predicting ABMD will reach $425.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $245.00 for Abiomed in the next year.
View the latest price targets for ABMD.

What is the current consensus analyst rating for Abiomed?

Abiomed currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABMD, but not buy more shares or sell existing shares.
View the latest ratings for ABMD.

What other companies compete with Abiomed?

How do I contact Abiomed's investor relations team?

Abiomed's physical mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider's listed phone number is 978-646-1400 and its investor relations email address is [email protected] The official website for Abiomed is www.abiomed.com.

Legend Who Bought Amazon In 1998 Says: Now Is The Time
Wall street legend Chris Rowe says there’s a huge stock market event looming - and he’s revealing his #1 pick for free.
pixel